Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Janssen Research & Development, LLC
Seagen Inc.
Eli Lilly and Company
Pfizer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of California, Irvine
City of Hope Medical Center
RemeGen Co., Ltd.
Amgen
Genmab
Astellas Pharma Inc
Debiopharm International SA
Pfizer
BeOne Medicines
M.D. Anderson Cancer Center
University of Maryland, Baltimore
Amgen
Washington University School of Medicine
Merck Sharp & Dohme LLC
AstraZeneca
Eli Lilly and Company
HC Biopharma Inc.
NRG Oncology
Janssen Research & Development, LLC
NRG Oncology
Eli Lilly and Company
Dana-Farber Cancer Institute
Abramson Cancer Center at Penn Medicine
Merck Sharp & Dohme LLC
Boehringer Ingelheim
National Institutes of Health Clinical Center (CC)
Shanghai Zhongshan Hospital
National Cancer Institute (NCI)
AstraZeneca
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
Boehringer Ingelheim
Rutgers, The State University of New Jersey
University Health Network, Toronto
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
Debiopharm International SA
Hoffmann-La Roche
Blueprint Medicines Corporation
Xijing Hospital
National Cancer Institute (NCI)
AstraZeneca